万孚生物：11月14日召开董事会会议

Core Viewpoint - Wanfu Biotech (SZ 300482) announced the convening of its 17th meeting of the 5th Board of Directors on November 14, 2025, to review documents including the proposal to re-evaluate and postpone certain fundraising projects [1] Company Summary - For the fiscal year 2024, Wanfu Biotech's revenue composition is as follows: diagnostic products account for 97.59%, while other products account for 2.41% [1] - As of the report date, Wanfu Biotech has a market capitalization of 10.3 billion yuan [1]